Trial Profile
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 06 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2023.
- 28 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.
- 22 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2022.